Therapy: Risk of metformin use in patients with T2DM and advanced CKD

Guntram Schernthaner; Marie Helene Schernthaner-Reiter

doi:10.1038/nrendo.2015.132

Therapy: Risk of metformin use in patients with T2DM and advanced CKD

Nat Rev Endocrinol. 2015 Dec;11(12):697-9. doi: 10.1038/nrendo.2015.132. Epub 2015 Aug 18.

Authors

Guntram Schernthaner¹, Marie Helene Schernthaner-Reiter²

Affiliations

¹ Rudolfstiftung Hospital, Department of Medicine 1, Juchgasse 25, 1030 Vienna, Austria.
² Clinical Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

PMID: 26284445
DOI: 10.1038/nrendo.2015.132

Abstract

In a new study published in The Lancet Diabetes & Endocrinology, metformin use is associated with significantly increased all-cause mortality in patients with type 2 diabetes mellitus and stage 5 chronic kidney disease (CKD). The findings support current recommendations that metformin should not be used in patients with stage 5 CKD.

Publication types

Comment

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / mortality*
Humans
Hypoglycemic Agents / adverse effects*
Metformin / adverse effects*
Renal Insufficiency, Chronic / complications*
Renal Insufficiency, Chronic / mortality*

Substances

Hypoglycemic Agents
Metformin